Next Generation Risk Assessment to Address Disease-Related Vulnerability-A Proof of Concept for the Sunscreen Octocrylene

Overview

Journal Toxics

Date 2025 Feb 25

PMID 39997925

Authors

Maria-Elena Fernandez-Martin

Jose V Tarazona

Affiliations

Soon will be listed here.

Abstract

Risk assessment for cosmetics in the European Union (EU) are triggered by a ban on animal testing and concerns of endocrine disruption (ED). The risk assessment focuses on healthy populations and, for potential ED, includes specific developmental stages as vulnerable due to specific concerns on endocrine effects. However, the assessment focuses on healthy individuals and does not consider that some pathologies may increase dermal absorption and even vulnerability to endocrine disruptors. Data from the EU risk assessment, human pharmacokinetic studies and ToxCast bioactivity were combined in a hypothesis-driven Next-Generation Risk Assessment to identify possible risk drivers for vulnerable populations including oncological patients and atopic dermatitis. In vitro effects are observed at concentration in the order of measured plasmatic levels under normal use patterns. The induction of hepatic enzymes is the most relevant bioactivity endpoint, in line with animal findings. The information on endocrine potential is inconclusive, and the possibility for skin effects and endocrine mechanism linked to tumor induction require further elucidation. The information on octocrylene (CAS number: 6197-30-4) bioactivity is limited, lacking information on the metabolites and the immunotoxicity potential, particularly relevant for oncological patients.

References

Berardesca E, Zuberbier T, Sanchez Viera M, Marinovich M . Review of the safety of octocrylene used as an ultraviolet filter in cosmetics. J Eur Acad Dermatol Venereol. 2019; 33 Suppl 7:25-33. DOI: 10.1111/jdv.15945. View

Apel P, Lamkarkach F, Lange R, Sissoko F, David M, Rousselle C . Human biomonitoring guidance values (HBM-GVs) for priority substances under the HBM4EU initiative - New values derivation for deltamethrin and cyfluthrin and overall results. Int J Hyg Environ Health. 2022; 248:114097. DOI: 10.1016/j.ijheh.2022.114097. View

Matta M, Florian J, Zusterzeel R, Pilli N, Patel V, Volpe D . Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. JAMA. 2020; 323(3):256-267. PMC: 6990686. DOI: 10.1001/jama.2019.20747. View

Gustafson E, Debruyne C, Troyer O, Rogiers V, Vinken M, Vanhaecke T . Screening of repeated dose toxicity data in safety evaluation reports of cosmetic ingredients issued by the Scientific Committee on Consumer Safety between 2009 and 2019. Arch Toxicol. 2020; 94(11):3723-3735. PMC: 7603458. DOI: 10.1007/s00204-020-02868-2. View

Apel P, Rousselle C, Lange R, Sissoko F, Kolossa-Gehring M, Ougier E . Human biomonitoring initiative (HBM4EU) - Strategy to derive human biomonitoring guidance values (HBM-GVs) for health risk assessment. Int J Hyg Environ Health. 2020; 230:113622. DOI: 10.1016/j.ijheh.2020.113622. View

Bury D, Belov V, Qi Y, Hayen H, Volmer D, Bruning T . Determination of Urinary Metabolites of the Emerging UV Filter Octocrylene by Online-SPE-LC-MS/MS. Anal Chem. 2017; 90(1):944-951. DOI: 10.1021/acs.analchem.7b03996. View

Api A, Belsito D, Bruze M, Cadby P, Calow P, Dagli M . Criteria for the Research Institute for Fragrance Materials, Inc. (RIFM) safety evaluation process for fragrance ingredients. Food Chem Toxicol. 2014; 82 Suppl:S1-S19. DOI: 10.1016/j.fct.2014.11.014. View

Wollenberg A, Christen-Zach S, Taieb A, Paul C, Thyssen J, de Bruin-Weller M . ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020; 34(12):2717-2744. DOI: 10.1111/jdv.16892. View

Hoogstraaten M, Vriend J, De Leeuw V, Negro S, Moors E, Kienhuis A . Animal-free safety assessment of chemicals: an innovation system perspective. Arch Toxicol. 2024; 99(1):43-56. PMC: 11742464. DOI: 10.1007/s00204-024-03878-0. View

10.

Rogiers V, Benfenati E, Bernauer U, Bodin L, Carmichael P, Chaudhry Q . The way forward for assessing the human health safety of cosmetics in the EU - Workshop proceedings. Toxicology. 2020; 436:152421. DOI: 10.1016/j.tox.2020.152421. View

11.

Bury D, Weber T, Ebert K, Zulz S, Bruning T, Koch H . Increasing exposure to the UV filters octocrylene and 2-ethylhexyl salicylate in Germany from 1996 to 2020: Human biomonitoring in 24-h urine samples of the German Environmental Specimen Bank (ESB). Environ Int. 2023; 182:108334. DOI: 10.1016/j.envint.2023.108334. View

12.

Alexander-White C, Bury D, Cronin M, Dent M, Hack E, Hewitt N . A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment. Regul Toxicol Pharmacol. 2022; 129:105094. DOI: 10.1016/j.yrtph.2021.105094. View

13.

Liu X, Michael S, Bharti K, Ferrer M, Song M . A biofabricated vascularized skin model of atopic dermatitis for preclinical studies. Biofabrication. 2020; 12(3):035002. PMC: 7457159. DOI: 10.1088/1758-5090/ab76a1. View

14.

Halling-Overgaard A, Kezic S, Jakasa I, Engebretsen K, Maibach H, Thyssen J . Skin absorption through atopic dermatitis skin: a systematic review. Br J Dermatol. 2016; 177(1):84-106. DOI: 10.1111/bjd.15065. View

15.

Mansouri K, Kleinstreuer N, Abdelaziz A, Alberga D, Alves V, Andersson P . CoMPARA: Collaborative Modeling Project for Androgen Receptor Activity. Environ Health Perspect. 2020; 128(2):27002. PMC: 7064318. DOI: 10.1289/EHP5580. View

16.

Hiller J, Klotz K, Meyer S, Uter W, Hof K, Greiner A . Systemic availability of lipophilic organic UV filters through dermal sunscreen exposure. Environ Int. 2019; 132:105068. DOI: 10.1016/j.envint.2019.105068. View

17.

Browne P, Judson R, Casey W, Kleinstreuer N, Thomas R . Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model. Environ Sci Technol. 2015; 49(14):8804-14. DOI: 10.1021/acs.est.5b02641. View

18.

Matta M, Zusterzeel R, Pilli N, Patel V, Volpe D, Florian J . Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. JAMA. 2019; 321(21):2082-2091. PMC: 6549296. DOI: 10.1001/jama.2019.5586. View

19.

Fernandez-Martin M, Tarazona J . Market analysis of the presence of endocrine disrupting chemicals in cosmetic products intended for oncological patients and other vulnerable groups. Eur J Dermatol. 2024; 34(1):40-50. DOI: 10.1684/ejd.2024.4615. View

20.

Berggren E, White A, Ouedraogo G, Paini A, Richarz A, Bois F . Ab initio chemical safety assessment: A workflow based on exposure considerations and non-animal methods. Comput Toxicol. 2017; 4:31-44. PMC: 5695905. DOI: 10.1016/j.comtox.2017.10.001. View